NOMOCAN PHASE I - DEVELOPMENT OF THERAPEUTIC OR PREVENTATIVE TECHNOLOGIES FOR TREATMENT OR PREVENTION OF PEDIATRIC CANCERS AND/OR RARE CANCERS SBIR CONTRACTPHASE I - DEVELOPMENT OF THERAPEUTIC OR PRE

Pancreatic ductal adenocarcinoma (PDAC) is predicted to be the second leading cause of cancer-related deaths by 2030 with a 5-year overall survival rate is only about 13%. For the majority of PDAC patients with metastatic PC, the current standard of care is systemic chemotherapy, which only extends survival by a few months. There is a critical need for less toxic, more potent targeted therapeutics for PDAC. Details in Aims Project Number: 75N91025C00050-0-9999-1 | Fiscal Year: 2025 | NIH Institute/Center: National Cancer Institute (NCI) | Principal Investigator: EHSAN YAZDI | Institution: NOMOCAN PHARMACEUTICALS, LLC, BROOKLYN, NY | Award Amount: $499,166 | Activity Code: N43 View on NIH RePORTER: https://reporter.nih.gov/project-details/11458979